Overview

Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)

Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the relative effect size of standard IV and oral iron treatment of RLS with Iron deficiency anemia (IDA) and to determine the time course of treatment response.
Phase:
Phase 2
Details
Lead Sponsor:
Auerbach Hematology Oncology Associates P C
Collaborator:
AMAG Pharmaceuticals, Inc.
Treatments:
Ferrosoferric Oxide
Iron